TAVR in the 65-75 Year Old: How Do You Choose?
Kimberly A. Skelding, M.D., FSCAI, Robert Wood Johnson Barnabas Health, Jersey City, NJ
Kimberly A. Skelding, M.D., FSCAI, Robert Wood Johnson Barnabas Health, Jersey City, NJ
Learning Objectives:
- Question data on valve durability, showing major trials and flaws.
- Give two patient examples in which TAVR first is controversial, but best fit for a young patient (and outcome shown if possible).
- Describe concepts of shared decision making, presence in guidelines.
Keywords: Structural Heart Disease (SHD) and TAVI/TAVR/Aortic Valve